Loading
Drug trials must be registered before they start so results cannot be hidden or reshaped. Studies that claim a biomarker predicts outcome should be registered too.
Biomarker studies suffer from selective reporting, flexible cut-points and unreported failed validations. A registry for biomarker validation studies (marker, assay, population, pre-specified analysis and cut-point, primary performance measure), required by journals for prognostic and predictive claims, would enable tracking of validation attempts including the negative ones, and reduce analytic flexibility.
Shares Registered reports for cancer biology: the plan is peer-reviewed before the result, Preclinical results do not reproduce.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Preclinical results do not reproduce, Biomarkers are not validated or standardised.
Shares ClinicalTrials.gov, Preclinical results do not reproduce.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.